MAPK8 and colorectal carcinoma: To determine whether the activation of these kinases mediates DBG-induced apoptosis, we pretreated CRC cells with the JNK inhibitor SP600125 (4 μM) or the p38 MAPK inhibitor SB203580 (5 μM), and determined the viability of DBG-treated CRC cells (Fig. 3F and 3G).